Myriad Genetics is Exclusive Licensee of New Mayo Clinic Patent on Amyloid Lowering Drugs
01-Jul-2005 -
Myriad Genetics, Inc. announced the issuance of Patent No. 6,911,466 entitled, "Ab42 Lowering Agents". Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent covers methods of using a broad class of compounds known as selective amyloid beta 42 ...
Alzheimer's disease
gene mutations
genetic mutations
+2